| scholarly article | Q13442814 |
| P50 | author | Raj C. Shah | Q46413647 |
| Ana W Capuano | Q104617620 | ||
| P2093 | author name string | Debra A Fleischman | |
| Jerry R Colca | |||
| Dawn C Matthews | |||
| Randolph D Andrews | |||
| James T VanderLugt | |||
| P2860 | cites work | Mitochondrial Aβ A potential cause of metabolic dysfunction in Alzheimer's disease | Q22242986 |
| Brain fuel metabolism, aging, and Alzheimer's disease | Q24625859 | ||
| “Mini-mental state” | Q25938989 | ||
| Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention | Q26865358 | ||
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease | Q28259585 | ||
| Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins | Q28488095 | ||
| Methylphenidate decreased the amount of glucose needed by the brain to perform a cognitive task | Q33328509 | ||
| Microglial activation and amyloid deposition in mild cognitive impairment: a PET study | Q33634089 | ||
| Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative | Q33798435 | ||
| Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. | Q33939971 | ||
| Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? | Q34464761 | ||
| National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease | Q34635272 | ||
| Brain aging, Alzheimer's disease, and mitochondria | Q35533354 | ||
| Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline | Q35858095 | ||
| Mitoenergetic failure in Alzheimer disease | Q36522646 | ||
| Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer | Q36705829 | ||
| Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. | Q36747796 | ||
| Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease | Q37219754 | ||
| Food for thought: the importance of glucose and other energy substrates for sustaining brain function under varying levels of activity | Q37826510 | ||
| Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease | Q37949572 | ||
| Altering mitochondrial dysfunction as an approach to treating Alzheimer's disease | Q38030125 | ||
| Mitochondrial target of thiazolidinediones | Q38207747 | ||
| The perils of Alzheimer's drug development | Q42560979 | ||
| A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease | Q42866942 | ||
| The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease | Q42932695 | ||
| Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases | Q44635317 | ||
| Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus | Q46146314 | ||
| Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease | Q48218480 | ||
| Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study | Q48387371 | ||
| Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer's disease and decreases it in wild-type mice | Q48475665 | ||
| Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. | Q51411852 | ||
| Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies | Q84140005 | ||
| 2013 Alzheimer's disease facts and figures | Q86421768 | ||
| P433 | issue | 6 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 564-573 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | Current Alzheimer Research | Q5195031 |
| P1476 | title | An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease | |
| P478 | volume | 11 |
| Q33808884 | Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets. |
| Q90679732 | Drug Repurposing in Parkinson's Disease |
| Q39022532 | Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends |
| Q48402725 | Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease |
| Q92743677 | Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer |
| Q38610829 | The TZD insulin sensitizer clue provides a new route into diabetes drug discovery |
| Q52699083 | Treating fatty liver disease by modulating mitochondrial pyruvate metabolism. |
Search more.